

Oncology Pipeline Analytics

Trials, Drug Classes,
Indications, Correlations and
Strategies

Report Brochure




Greystone
Research Associates

Greystone Research Associates is pleased to announce the publication of a new market assessment. **Oncology Pipeline Analytics: Trials, Drug Classes, Indications, Correlations and Strategies** is a comprehensive evaluation and analysis of the technology, products and participants providing the driving force behind the accelerating oncology clinical development market. The study is designed to provide drug company decision makers, healthcare marketers, and supply chain participants with a detailed understanding of the economics, technologies, disease segments, and commercial opportunities for oncology drug therapeutics. Provider organization business managers, healthcare administrators and investors will also benefit from this study.

Converging Factors Driving the Oncology Drug Development Landscape

As immunotherapeutics in general – and immuno-oncology in particular - move to the forefront, the major oncology drug developers are beginning to align with specific therapeutic approaches, such as PARP and PD-1/PD-L1. Our analytics analysis of current active oncology trial data reveals these factors and how they are affecting the oncology drug development landscape.

By combining data on the oncology drug delivery landscape with the relational power of analytics we've created a unique information resource that provides insight and clarity to market sector activity and competitive positioning within the oncology therapeutics space. By grouping and formatting information into visualizations that are easy to digest, readers gain a new and revealing perspective on the oncology drug development market.



Executive Summary

Drug Development Challenges in Oncology Therapeutics

Biological Drugs
Biosimilars
Small Molecule Drugs

Leading Development-stage Oncology Therapeutics

atezolizumab
PD-1 & PD-L1
durvalumab
HDAC Inhibitors
nivolumab
BET Inhibitors
CAR-T cell therapy
Oncolytic Viruses
STAT3 Inhibitors
carbozantinib
Anti-LAG3 mAb
BTK Inhibitor
PARP Inhibitors

Oncology Clinical Trial Activity by Sponsor & Disease Segment

Bladder Cancer
Brain Cancer
Breast Cancer
Colorectal Cancer
Gastric Cancer
Head and Neck Cancer
Hematological Malignancies
Hepatic Cancer
Kidney Cancer
Leukemia
Lung Cancer
Lymphoma
Multiple Myeloma
Ovarian Cancer
Pancreatic Cancer
Prostate Cancer
Sarcomas
Skin Cancer
Solid Tumors
Other Cancers

Company Profiles

Tables, Charts and Visualizations

1. Pipeline Activity by Cancer Segment (Bubble Chart)
2. Sponsors of Active Oncology Trials (Heat Map)
3. New BLAs by Application 2005-2017 (Dot Matrix)
4. Biological Drug Ecosystem (Global Map)
5. atezolizumab – Trials by Disease Segment (Circle Grid)
6. PD-1 / PD-L1 Inhibitors - Trials by Disease Segment (Circle Grid)
7. PD-1 / PD-L1 Inhibitors – Active Trials by Sponsor (Pie Chart)
8. PD-1 / PD-L1 Inhibitors – Active Trials by Disease Segment (Pie Chart)
9. durvalumab - Trials by Disease Segment (Circle Grid)
10. durvalumab - Active Trials by Sponsor (Pie Chart)
11. durvalumab - Active Trials by Disease Segment (Pie Chart)
12. HDAC Inhibitors – Active Trials by Disease Segment (Circle Grid)
13. HDAC Inhibitors - Active Trials by Sponsor (Pie Chart)
14. HDAC inhibitors - Active Trials by Disease Segment (Pie Chart)
15. nivolumab – Active Trials by Disease Segment (Circle Grid)
16. nivolumab – Active Trials by Disease Segment (Pie Chart)
17. BET Inhibitors - - Active Trials by Disease Segment (Circle Grid)
18. BET Inhibitors - Active Trials by Sponsor (Pie Chart)
19. CAR-T cell therapy - Active Trials by Sponsor (Pie Chart)
20. CAR-T cell therapy - Active Trials by Disease Segment (Pie Chart)
21. Oncolytic Viruses – Active Trials by Disease Segment (Circle Grid)
22. Oncolytic Viruses - Active Trials by Sponsor (Pie Chart)
23. Oncolytic Viruses – Active Trials by Disease Segment (Circle Grid)
24. STAT3 Inhibitors – Active Trials by Sponsor (Pie Chart)
25. STAT3 Inhibitors – Active Trials by Disease Segment (Pie Chart)
26. carbozantinib - Active Trials by Disease Segment (Pie Chart)
27. Anti-LAG3 mAb - Active Trials by Sponsor (Pie Chart)
28. Anti-LAG3 mAb - Active Trials by Disease Segment (Pie Chart)
29. BTK Inhibitor - Active Trials by Sponsor (Pie Chart)
30. BTK Inhibitor - Active Trials by Disease Segment (Pie Chart)
31. PARP Inhibitors - Active Trials by Sponsor (Pie Chart)
32. PARP Inhibitors - Active Trials by Disease Segment (Pie Chart)
33. Bladder Cancer – Active Oncology Trials by Phase (Bar Graph)
34. Brain Cancer - Active Trials by Disease Segment (Bar Graph)
35. Breast Cancer - Active Trials by Disease Segment (Bar Graph)
36. Colorectal Cancer - Active Trials by Disease Segment (Bar Graph)
37. Gastric Cancer - Active Trials by Disease Segment (Bar Graph)
38. Head and Neck Cancer - Active Trials by Disease Segment (Bar Graph)
39. Hematological Malignancies - Active Trials by Disease Segment (Bar Graph)

40. Hepatic Cancer - Active Trials by Disease Segment (Bar Graph)
41. Kidney Cancer - Active Trials by Disease Segment (Bar Graph)
42. Leukemia - Active Trials by Disease Segment (Bar Graph)
43. Lung Cancer - Active Trials by Disease Segment (Bar Graph)
44. Lymphoma - Active Trials by Disease Segment (Bar Graph)
45. Multiple Myeloma - Active Trials by Disease Segment (Bar Graph)
46. Ovarian Cancer - Active Trials by Disease Segment (Bar Graph)
47. Pancreatic Cancer - Active Trials by Disease Segment (Bar Graph)
48. Prostate Cancer - Active Trials by Disease Segment (Bar Graph)
49. Sarcomas - Active Trials by Disease Segment (Bar Graph)
50. Skin Cancer - Active Trials by Disease Segment (Bar Graph)
51. Solid Tumors - Active Trials by Disease Segment (Bar Graph)
52. Other Cancers - Active Trials by Disease Segment (Bar Graph)
53. AbbVie – Clinical Trial Activity by Disease Segment (Bubble Chart)
54. AbbVie – Active Oncology Trial Details (Table)
55. AbbVie – Number of Active Oncology Trials by Drug Class (Heat Map)
56. Amgen – Clinical Trial Activity by Disease Segment (Bubble Chart)
57. Amgen – Active Oncology Trial Details (Table)
58. Amgen – Number of Active Oncology Trials by Drug Class (Heat Map)
59. AstraZeneca – Clinical Trial Activity by Disease Segment (Bubble Chart)
60. AstraZeneca – Active Oncology Trial Details (Table)
61. AsetraZeneca – Number of Active Oncology Trials by Drug Class (Heat Map)
62. Bayer Pharmaceuticals – Clinical Trial Activity by Disease Segment (Bubble Chart)
63. Bayer Pharmaceuticals - Active Oncology Trial Details (Table)
64. Bayer Pharmaceuticals – Number of Active Oncology Trials by Drug Class (Heat Map)
65. Boehringer Ingelheim – Clinical Trial Activity by Disease Segment (Bubble Chart)
66. Boehringer Ingelheim – Active Oncology Trial Details (Table)
67. Boston Biomedical – Clinical Trial Activity by Disease Segment (Bubble Chart)
68. Boston Biomedical - Active Oncology Trial Details (Table)
69. Bristol-Myers Squibb – Clinical Trial Activity by Disease Segment (Bubble Chart)
70. Bristol-Myers Squibb – Active Oncology Trial Details (Table)
71. Bristol-Myers Squibb – Active Oncology Trial Details (Table)
72. Bristol Myers Squibb – Number of Active Oncology Trials by Drug Class (Heat Map)
73. Celgene – Clinical Trial Activity by Disease Segment (Bubble Chart)
74. Celgene – Active Oncology Trial Details (Table)

75. Celgene – Number of Active Oncology Trials by Drug Class (Heat Map)
76. Celldex Therapeutics – Clinical Trial Activity by Disease Segment (Bubble Chart)
77. Celldex Therapeutics – Active Oncology Trial Details (Table)
78. Eisai – Clinical Trial Activity by Disease Segment (Bubble Chart)
79. Eisai – Active Oncology Trial Details (Table)
80. Eli Lilly – Clinical Trial Activity by Disease Segment (Bubble Chart)
81. Eli Lilly – Active Oncology Trial Details (Table)
82. Eli Lilly – Number of Active Oncology Trials by Drug Class (Heat Map)
83. EMD Serono- Clinical Trial Activity by Disease Segment (Bubble Chart)
84. EMD Serono – Active Oncology Trial Details (Table)
85. EMD Serono – Number of Active Oncology Trials by Drug Class (Heat Map)
86. Exelixis – Clinical Trial Activity by Disease Segment (Bubble Chart)
87. Exelixis – Active Oncology Trial Details (Table)
88. Genentech – Clinical Trial Activity by Disease Segment (Bubble Chart)
89. Genentech – Active Oncology Trial Details (Table)
90. Genentech – Active Oncology Trial Details (Table)
91. Genentech – Number of Active Oncology Trials by Drug Class (Heat Map)
92. Gilead Sciences – Clinical Trial Activity by Disease Segment (Bubble Chart)
93. Gilead Sciences – Active Oncology Trial Details (Table)
94. GlaxoSmithKline – Clinical Trial Activity by Disease Segment (Bubble Chart)
95. GlaxoSmithKline - Active Oncology Trial Details (Table)
96. Incyte – Clinical Trial Activity by Disease Segment (Bubble Chart)
97. Incyte –
98. Janssen Research & Development – Clinical Trial Activity by Disease Segment (Bubble Chart)
99. Janssen Research & Development – Active Oncology Trial Details (Table)
100. Janssen Research & Development – Number of Active Oncology Trials by Drug Class (Heat Map)
101. Karyopharm Therapeutics - Clinical Trial Activity by Disease Segment (Bubble Chart)
102. Karyopharm Therapeutics - Active Oncology Trial Details (Table)
103. Leap Therapeutics – Clinical Trial Activity by Disease Segment (Bubble Chart)
104. Leap Therapeutics – Active Oncology Trial Details (Table)
105. MacroGenics – Clinical Trial Activity by Disease Segment (Bubble Chart)

106. MacroGenics – Active Oncology Trial Details (Table)
107. MedImmune – Clinical Trial Activity by Disease Segment (Bubble Chart)
108. MedImmune – Active Oncology Trial Details (Table)
109. MedImmune – Number of Active Oncology Trials by Drug Class (Heat Map)
110. Merck – Clinical Trial Activity by Disease Segment (Bubble Chart)
111. Merck – Active Oncology Trial Details (Table)
112. Merck – Number of Active Oncology Trials by Drug Class (Heat Map)
113. Novartis Oncology – Clinical Trial Activity by Disease Segment (Bubble Chart)
114. Novartis Oncology – Active Oncology Trial Details (Table)
115. Novartis Oncology – Active Oncology Trial Details (Table)
116. Novartis Oncology – Active Oncology Trial Details (Table)
117. Novartis Oncology – Number of Active Oncology Trials by Drug Class (Heat Map)
118. Pfizer – Clinical Trial Activity by Disease Segment (Bubble Chart)
119. Pfizer – Active Oncology Trial Details (Table)
120. Pfizer – Number of Active Oncology Trials by Drug Class (Heat Map)
121. Roche – Clinical Trial Activity by Disease Segment (Bubble Chart)
122. Roche – Active Oncology Trial Details (Table)
123. Seattle Genetics – Clinical Trial Activity by Disease Segment (Bubble Chart)
125. Seattle Genetics – Active Oncology Trial Details (Table)
126. Takeda Technology – Clinical Trial Activity by Disease Segment (Bubble Chart)
127. Takeda Technology – Active Oncology Trial Details (Table)
128. Tesaro – Clinical Trial Activity by Disease Segment (Bubble Chart)
129. Tesaro - Active Oncology Trial Details (Table)

What You Will Learn

- Who are the leading developers in the current crop of oncology drugs in development? What are their activities and what is their position in therapeutic oncology markets?
- What are the most frequently trailed therapeutic oncology drugs? What is the clinical strategy? How many trials are under way?
- What are the major factors driving the oncology pipeline development market landscape?
- What is the size of the oncology clinical trial market today, who are the market share leaders, and what will the market share look like in 2024?
- How important are drug partnership relationships in the oncology drug development space?
- Which indications are the focus of the highest level of clinical trial activity? How well-positioned are the leading oncology drug suppliers as the pace of oncology product introductions accelerates?
- What are the significant economic, technology, and regulatory factors affecting the market?

Report Format and Availability

This report is available electronic format. A site license for a single physical location and a corporate license are also available. Custom licensing options to address specific company user requirements are available by calling client services at 603-595-4340, or by emailing clientservices@greystoneassociates.org.

Methodology

Research methodology is based on primary research in the form of in-depth interviews with key market participants, technology developers, distributors, industry experts, and market influencers, a list that includes regulatory officials, industry trade groups, and materials standards organizations.

Primary data is evaluated and normalized against secondary sources including trade journal articles, technical literature, industry publications, company data sheets and published information, and statistical data from government agencies and trade associations.

Forecasts and projections of market demand and future market activity are derived using standard modeling and statistical techniques.

About Greystone Associates

Greystone Associates is a medical technology consulting firm focused on the areas of medical market strategy, product commercialization, venture development, and market research. We assist medical and healthcare market participants in achieving their business objectives through the creation of detailed development strategies, product commercialization programs, and comprehensive market and technology research and analysis.

Our market research publications are designed, researched and written to provide timely and insightful information and data on focused market segments, with the aim of providing market participants with the essential knowledge to refine and execute their marketing plans and financial targets.

Ordering Information

Orders may be placed via postal mail, e-mail or fax. Orders not accompanied by a purchase order must contain a telephone number for verification, and clearly indicate the physical shipping address and billing address.

Payment

We accept the following forms of payment:

Company Check: Please make checks payable to 'Greystone Associates'

Credit Cards: We accept MasterCard, Visa and American Express

Wire Transfers: See 'Wire Transfers' below for more information

Orders Outside the U.S.

Orders must be prepaid via credit card, company check in US funds and drawn on a US bank, or wire transfer.

Email to
research@greystoneassociates.org

Wire Transfers: TD Banknorth
300 Franklin Street
Manchester, NH 03103
(Call for Account Information)

Mailing Address: Greystone Research Associates
Client Services
P.O. Box 1362
Amherst, NH 03031

Oncology Pipeline Analytics

Trials, Drug Classes, Indications, Correlations and Strategies

Select	Format	License	Price (U.S. Funds)	Total
<input type="checkbox"/>	PDF	Single User License	\$2,850.00	
<input type="checkbox"/>	PDF	Site License	\$4,500.00	
<input type="checkbox"/>	PDF	Corporate License	\$6,500.00	
Total Payment (U.S. funds)				

Method of Payment: Company Check    Wire Transfer (International)

Card Number: _____ Name on Card _____

Expiration Date: _____ Card CVV _____ Signature _____

Billing Information	Shipping Information
Name:	<input type="checkbox"/> Click here if same as Billing Information Name:
Title:	Title:
Company:	Company:
Street Address:	Street Address:
City,State/Province:	City,State/Province:
Country/Postal Code:	Country/Postal Code:
Phone:	Phone:
Fax:	Fax:
Email:	Email: